1. Introduction: need for antiviral drugs against highly pathogenic RNA viruses
===============================================================================

This paper, one of three that introduce a special issue of *Antiviral Research*, describes potential antiviral drug strategies that may be employed to treat or prevent infections with highly pathogenic RNA viruses. A second article reviews the epidemiology and pathogenesis of representative diseases, and a third discusses experimental sequence-based approaches to therapy ([@bib23], [@bib144]). Two other papers in this issue cover animal models of hemorrhagic fever ([@bib72]) or encephalitis ([@bib78]) caused by highly pathogenic RNA viruses, while others describe opportunities for research support and collaboration or focus on the treatment of specific diseases (see below).

Highly pathogenic RNA viruses belong to various virus families. These include the *Arenaviridae* (Lassa and Argentine hemorrhagic fever (AHF) viruses), the *Bunyaviridae* (Crimean-Congo hemorrhagic fever (CCHF) virus and hantaviruses), the *Coronaviridae* (severe acute respiratory syndrome (SARS) coronavirus), the *Filoviridae* (Marburg and Ebola virus), the *Flaviviridae* (yellow fever virus, Japanese encephalitis virus and other flaviviruses that cause encephalitis), the *Paramyxoviridae* (Nipah and Hendra virus), the *Orthomyxoviridae* (influenza) and the *Togaviridae* (chikungunya, and western, eastern and Venezuelan equine encephalitis viruses). In addition to pathogens that are a serious threat to human health, viruses such as the foot-and-mouth disease virus (*Picornaviridae*) and classical swine fever virus (*Flaviviridae*) are a threat to livestock, and can have an enormous impact on the economy (reviewed by [@bib69]).

At present, some 40 antiviral drugs have been formally licensed for use in humans, mostly for the treatment of infections with the human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpesviruses. The number of licensed antiviral drugs that can be used for the treatment of highly pathogenic RNA virus infections is very limited. These are for influenza, the M2 channel inhibitors, amantadine and rimantadine, and the neuraminidase inhibitors, oseltamivir and zanamivir. Ribavirin is licensed for the treatment of respiratory syncytial virus (RSV) and hepatitis C virus (HCV) infections and is also being used for the treatment of Lassa fever. There is thus an unmet need for potent inhibitors of RNA virus replication, which should have as broad a spectrum as possible. Here we will first discuss the use of licensed antiviral drugs for the treatment of infections caused by highly pathogenic RNA viruses. Next, we provide a (non-exhaustive) review of potential targets for inhibiting the replication of RNA viruses.

2. Licensed drugs against highly pathogenic RNA viruses
=======================================================

Because the market for drugs for the treatment or prophylaxis of infections with highly pathogenic RNA viruses is rather limited, very few such drugs have been brought to the market. Because influenza causes worldwide epidemics with significant morbidity and mortality, it is an exception to this rule (see paper by [@bib14]).

2.1. Influenza drugs {#sec1}
--------------------

For infections with the influenza virus, the M2 channel inhibitors (amantadine and rimantadine) and the neuraminidase inhibitors (oseltamivir and zanamivir) have been formally licensed.

### 2.1.1. M2 channel blockers

The first synthetic compound shown to inhibit influenza replication was amantadine ([Fig. 1](#fig1){ref-type="fig"}A). This compound blocks the migration of H^+^ ions *via* the viral M2 ion channel into the interior of the virus particles residing in the endosomes ([@bib38]). Acidification of the interior of the viral particle results in destabilization of the capsid and results in uncoating; amantadine prevents this acidification process and thus uncoating ([@bib79], [@bib42]). M2 channel inhibitors are, however, only effective against influenza A strains and resistance against the drugs develops readily ([@bib110]). In recent years, there has been a dramatic increase in the prevalence of amantadine-resistant influenza virus strains (both seasonal influenza and H5N1 avian influenza). The extensive use of amantadine in poultry farms in Asia may be one of reasons of the high amantadine-resistance incidence ([@bib26], [@bib77]).Fig. 1Structure of amantadine (A) and rimantadine (B).

### 2.1.2. Neuraminidase inhibitors

The mechanism by which influenza virus is released from the host cell by the viral neuraminidase has been extensively documented. After budding from the host cell, the viral hemagglutinin interacts with the host cell receptor (a glycoprotein) bearing *N*-acetylneuraminic acid (NANA). The neuraminidase cleaves off NANA from the cell-surface glycoprotein at a specific bond, the sialic acid linked to galactose by an alfa 2,3 or alfa 2,6 linkage. This enables the progeny virus to leave the infected cells and to spread to other host cells. Inhibition of the neuraminidase prevents virus release and thus spread of the virus ([@bib112], [@bib113]).

The neuraminidase inhibitors were designed following a similar "transition-state" principle ([@bib1]) as applied for the peptidomimetic HIV protease inhibitors. This provided the influenza inhibitors DANA (2-deoxy-2,3-didehydro-*N*-acetylneuraminic acid, [Fig. 2](#fig2){ref-type="fig"}A) and FANA (2-deoxy-2,3-didehydro-*N*-trifluoroacetylneuraminic acid, [Fig. 2](#fig2){ref-type="fig"}B) and further rational design led to the development of the neuraminidase inhibitors zanamivir ([Fig. 2](#fig2){ref-type="fig"}C) and oseltamivir ([Fig. 2](#fig2){ref-type="fig"}D) ([@bib157], [@bib92]). Both compounds are highly potent inhibitors of the influenza neuraminidase and influenza A and B virus replication *in vitro* and *in vivo* (mice, ferrets). They are both prophylactically and therapeutically effective against influenza in humans (reviewed by [@bib42]). The H274Y mutation may engender resistance of both influenza A H1N1 and influenza A H5N1 to oseltamivir but not zanamivir. In both H5N1 and H1N1 neuraminidases, tyrosine at position 252 is involved in a network of hydrogen bonds, with histidine at position 274 ([@bib132]).Fig. 2Structure of DANA (A), FANA (B), zanamivir (C), oseltamivir (D) and peramivir (E).

Further insight into the structure of the type 1 neuraminidase suggests new opportunities for the future design of new neuraminidase inhibitors ([@bib132]). Peramivir ([Fig. 2](#fig2){ref-type="fig"}E) is a cyclopentane neuramidinase inhibitor that, like oseltamivir and zanamivir, acts as a sialic acid analogue transition-state intermediate in the neuraminidase active site. The development of peramivir is supported by the US Department of Health and Human Services (<http://www.hhs.gov/news/press/2007pres/20070104.html>). An injectable version of peramivir is being developed, as is also the case for zanamivir (see also [@bib14]). The availability of an injectable neuraminidase inhibitor may be an important asset in treating patients hospitalized with severe and potentially life-threatening influenza; an injectable formulation may ensure appropriate dosing which may be a concern with oral or inhaled anti-influenza agents.

2.2. Ribavirin
--------------

Ribavirin (1-β-[d]{.smallcaps}-ribofuranosyl-1,2,4-triazole-3-carboxamide, [Fig. 3](#fig3){ref-type="fig"}A) is a broad-spectrum inhibitor of RNA virus replication, that has been formally approved to treat HCV infections in combination with pegylated interferon and in aerosol form for the treatment of pediatric RSV infections. The drug has also been used experimentally against a number of other conditions, including Lassa fever (see [@bib91]), CCHF virus ([@bib57]) and hantaviruses ([@bib88]). The synthesis and antiviral activity of ribavirin was first reported in the early 1970s. The compound was found to inhibit the replication of a number of viruses (almost all of which were RNA viruses) *in vitro* and was shown to exert a protective effect in some experimental animal models ([@bib140], [@bib85]). Ribavirin has since been shown to inhibit the *in vitro* replication of virtually any RNA virus studied, although the potency may vary considerably, depending on the nature of the virus ([@bib74]).Fig. 3Structure of ribavirin (A), viramidine (B), levovirin (C), mizoribine (D) and EICAR (E).

### 2.2.1. Spectrum of activity and molecular mechanism of action

Although almost all RNA viruses are sensitive to the *in vitro* antiviral activity of ribavirin, some viruses are more susceptible than others. Overall, ribavirin is not very potent as an antiviral drug, and 50% effective concentrations (EC~50~) values are mostly (well above) 1 μM. In particular the replication of RSV is relatively efficiently inhibited by ribavirin; other viruses such as several picorna- flavi-, and filoviridae are less susceptible to the drug. Ribavirin was reported to inhibit the replication of several arenaviruses, including Lassa virus in cell culture ([@bib81], [@bib108], [@bib4], [@bib76]) and has beneficial effects in experimental animal models of Lassa fever ([@bib145], [@bib86], [@bib52]). *In vitro* antiviral activity of ribavirin has also been demonstrated against bunyaviruses including CCHF virus, Rift Valley fever virus and hantaviruses ([@bib159], [@bib82], [@bib137]). Ribavirin inhibits the replication of coronavirus, including the SARS-coronavirus ([@bib133], [@bib12]) and flaviviruses ([@bib118]) but has not shown efficacy in experimental infections in animals with these viruses. Likewise, ribavirin is not effective in animal models of filovirus infections ([@bib82]). Like other paramyxoviruses such as RSV, Nipah virus is relatively sensitive to ribavirin in cell culture and limited efficacy of the compound has been demonstrated in animal models ([@bib143], [@bib67]). Ribavirin has also been shown to inhibit the *in vitro* replication of alphaviruses such as Chikungunya and equine encephalitis viruses ([@bib27], [@bib105]).

Despite the fact that the antiviral activity of ribavirin was reported 35 years ago, the molecular mechanism by which the compound exerts its antiviral activity still remains a matter of debate. Inosine 5′-monophosphate (IMP) dehydrogenase, a cellular enzyme that converts IMP to xanthosine 5′-monophosphate in the *de novo* synthesis pathway of guanosine 5′-monophosphate (GMP), is inhibited by ribavirin 5′-monophosphate ([@bib147]) ([Fig. 4](#fig4){ref-type="fig"} ). The subsequent depletion of intracellular GTP-pools compromises the supply of this nucleotide for the synthesis of progeny viral RNA. This mechanism provided a reasonable explanation for the broad-spectrum anti-RNA virus activity of ribavirin ([@bib147]). Ribavirin-resistant Sindbis virus was shown to carry mutations in the viral guanylyltransferase gene. This is in line with the observation that drug-resistant Sindbis virus replicates relatively efficiently in cells with low intracellular GTP concentrations, either induced by ribavirin or by other IMP dehydrogenase inhibitors ([@bib103], [@bib134]).Fig. 4Mechanism of action of ribavirin. Target enzyme: IMP dehydrogenase. Ribavirin 5′-monophosphate inhibits the conversion of IMP to XMP resulting in a reduced supply of GTP, and indirectly a reduced supply of ATP.

Later, several other mechanisms were suggested that may contribute to the antiviral activity of ribavirin, including (i) inhibition of viral capping as mediated by an effect on the viral guanylyltransferase or inhibition of viral methyltransferases of viruses that encode such enzymes ([@bib70], [@bib21], [@bib22], [@bib15]), (ii) inhibition of RNA-dependent RNA polymerase activity by ribavirin 5′-triphosphate as shown for influenza and HCV ([@bib58], [@bib101], [@bib21]) and (iii) inhibition of the viral helicase activity (as suggested for reoviruses) ([@bib130]). The poliovirus RNA-dependent RNA polymerase was shown to incorporate ribavirin opposite to cytidine and uridine in the growing RNA chain ([@bib36]) and poliovirus, that was cultured in the presence of high concentrations of ribavirin (1 mM), accumulated 10-fold more mutations in its genome than virus grown in untreated cultures. The accumulation of mutations in the viral genome results in a process called error catastrophe ([@bib37]). A single mutation (G64S) in the poliovirus RNA-dependent RNA polymerase gene was found to increase the enzyme\'s fidelity and to render the virus less susceptible to the mutagenic effect of ribavirin ([@bib128]). Error catastrophe has also been proposed to be involved in the antiviral activity of ribavirin against Hantaan virus replication ([@bib137]) as well as the replication of foot-and-mouth disease virus ([@bib2]) and GB virus B virus ([@bib95]).

It remains, however, unclear to what extent error catastrophe, depletion of intracellular GTP-pools or one or more of the other proposed mechanisms contribute to the actual antiviral effect of ribavirin, and whether or not these effects also play a part in the antiviral activity of the compound *in vivo*. For flaviviruses and paramyxoviruses, we demonstrated that GTP pool depletion is the predominant mechanism by which ribavirin exerts its antiviral activity ([@bib96]); for flaviviruses, error catastrophe does not appear to contribute to the *in vitro* antiviral activity of the drug ([@bib97]).

### 2.2.2. Clinical use of ribavirin

Ribavirin was first approved in 1985 for the aerosol treatment of severe respiratory tract infections in children caused by the RSV. Until today, the actual clinical benefit of this treatment has been debated. Review of reported cases and clinical trials indicate that ribavirin may reduce the duration of mechanical ventilation and may reduce days of hospitalization. In addition, use of ribavirin may be associated with a decrease in the long-term incidence of recurrent wheezing following RSV disease ([@bib156]).

In patients chronically infected with HCV, ribavirin alone induces either a transient early decline or no decrease in HCV viral load, but, in combination with interferon, it significantly improves long-term response rates. The precise mechanism by which the compound improves the efficacy of interferon ([@bib48]) remains a matter of debate. Conflicting evidence has been reported regarding the potential of ribavirin to induce error catastrophe. On the one hand, no increase in mutation rate was detected in HCV genomes isolated from patients treated with ribavirin ([@bib99], [@bib125], [@bib126]) or ribavirin/interferon combination therapy ([@bib135], [@bib125], [@bib126], [@bib31], [@bib32]), on the other hand, in a subset of ribavirin-treated, HCV-infected patients, an increased number of mutations was observed ([@bib6]).

Ribavirin is used off-label for the treatment of Lassa fever; this use, however, is based on a single published study using a historical control group ([@bib107]). Intravenously administrated ribavirin appears to be more efficacious than when the drug is given orally, which is likely related to the fact that plasma concentrations reached following oral dosing are lower. For the treatment of Lassa fever, ribavirin is effective when given in the early stages of the course of the disease, but reduced or no efficacy was noted if ribavirin was given in the late stages of the disease ([@bib107], [@bib136]). The drug has also been used as post-exposure prophylaxis, but there are no published data to support this use. For further information on the use of ribavirin in the treatment of Lassa fever or another arenavirus infection, Argentine hemorrhagic fever, the reader is referred to other articles by [@bib91] and [@bib56].

Ribavirin showed a beneficial effect in a placebo-controlled study in patients infected with Hantaan virus (hemorrhagic fever with renal syndrome, HFRS) when treatment was initiated early in the course of the disease ([@bib83]). However, in two double-blind placebo-controlled studies in patients infected with a New World hantavirus (hantavirus (cardio)pulmonary syndrome, HPS) the drug had no, or virtually no, clinical efficacy ([@bib29], [@bib35]). The lack of activity may be related to the phase of infection and severity of the disease; which may call for early intervention (see [@bib88]). HPS is to a large extent an immunopathological syndrome; thus even the most effective antiviral may be of little utility without controlling the deleterious host response that is in full-force at the time patients seek medical attention.

Ribavirin has also been used, administered either orally or intravenously, to treat CCHF ([@bib60], [@bib104], [@bib20]). As described by [@bib57], evidence for efficacy is limited to observational studies. Placebo-controlled studies, may be for ethical reasons impossible to perform in patients with CCHF. Despite this shortcoming, post-exposure prophylaxis and treatment with ribavirin in every stage of the disease is recommended Ribavirin has also been used without much success as a first-line-of-defence against emerging viruses such as Nipah virus and the SARS-coronavirus ([@bib33], [@bib146]). Finally, ribavirin is not effective in the treatment of filovirus infections (reviewed by [@bib13]) or for the treatment of Japanese encephalitis, yellow fever or other flaviviral infections (see articles by [@bib71], [@bib109]).

### 2.2.3. Ribavirin analogues and prodrugs

To increase the oral bioavailability of ribavirin and to decrease side-effects such as a dose-limiting hemolytic anemia, various prodrugs of ribavirin have been developed. Viramidine ([Fig. 3](#fig3){ref-type="fig"}B) is an aminated prodrug of ribavirin that is deaminated *in vivo* by adenosine deaminase ([@bib161]). The drug, following absorption, is rapidly converted to ribavirin ([@bib98]). The activity of viramidine on influenza virus replication was comparable to that of ribavirin ([@bib141]). Viramidine is being developed for the treatment of HCV infection.

Several other analogues of ribavirin, such as levovirine and mizoribine have been studied. Levovirin (ICN-17261, [Fig. 3](#fig3){ref-type="fig"}C) is the [l]{.smallcaps}-analogue of ribavirin; it does not undergo phosphorylation, and has no antiviral activity *in vitro*. It has been proposed that levovirin possesses, akin to ribavirin, immunomodulatory activity ([@bib150], [@bib151]). Clinical studies with levovirin in HCV-infected patients were unsuccessful, which suggest that the immunomodulatory activity of levovirin is not sufficient to result in clinical efficacy. Levovirin was not further developed ([@bib59]).

Mizoribine ([Fig. 3](#fig3){ref-type="fig"}D) is a hydroxylated analogue of ribavirin and inhibits, akin to ribavirin, cellular IMP dehydrogenase; this molecule has been developed as an immunosuppressive agent ([@bib65]) rather than an antiviral agent, although some antiviral activity in combination with other agents has been reported ([@bib133], [@bib115], [@bib163], [@bib148]). A potent reversible uncompetitive IMP dehydrogenase inhibitor, VX-497 (imepodib, [Fig. 5](#fig5){ref-type="fig"} ), structurally unrelated to other inhibitors of this enzyme, was developed and shown to exhibit *in vitro* antiviral activity that was superior to that of ribavirin. However, the compound was not further developed ([@bib105]).Fig. 5Structure of VX-497.

### 2.2.4. Ribavirin as a lead for improved analogues?

Although ribavirin exerts broad-spectrum activity *in vitro*, its clinical use is, as discussed, limited to only a few viral infections. The mechanism by which ribavirin inhibits viral replication varies with the virus studied and can be considered as not very selective (GTP depletion, error catastrophe, etc.). The design of safe and more potent analogues of ribavirin with broad-spectrum activity that can be used in the treatment of a variety of RNA virus infections will therefore likely be very difficult to achieve. EICAR, the 5-ethynyl analogue of ribavirin ([Fig. 3](#fig3){ref-type="fig"}E) was shown to be *in vitro* roughly 10- to 30-fold more potent in inhibiting the replication of various RNA viruses ([@bib96]). However, this improved activity came at the price of a concomitant increase in toxicity; which is explained by the fact that the 5′-monophosphate metabolite of EICAR is also more potent than ribavirin monophosphate in inhibiting the IMP dehydrogenase ([@bib8]).

3. Viral targets for therapy
============================

3.1. Entry and uptake
---------------------

The initial interaction of the virus with the host cell represents an attractive target for therapeutic intervention. We will discuss briefly possible approaches to inhibit these early events in the replication cycle of some RNA viruses, including picorna-, corona- arena- and paramyxoviruses, for which strategies that inhibit entry or uptake have been reported.

### 3.1.1. Picornaviruses

The attachment of picornaviruses occurs through binding of the host cell receptor into a canyon situated around each 5-fold vertex of the capsid; binding of the receptor is believed to trigger also the uncoating process. Binding of specific molecules in a pocket immediately underneath the floor of the canyon, results in an increase in protein rigidity and stabilizes the particle in such a manner that uncoating cannot proceed (reviewed by [@bib44]). Numerous compounds have been identified that inhibit picornavirus replication by specific interaction with this pocket. Two compounds that bind into this pocket, pleconaril ([Fig. 6](#fig6){ref-type="fig"}A) and pirodavir ([Fig. 6](#fig6){ref-type="fig"}B) have been evaluated in the clinical setting, but further development has been halted because of lack of activity or adverse side-effects ([@bib44]).Fig. 6Structure of pleconaril (A) and pirodavir (B).

### 3.1.2. Coronaviruses

Many enveloped viruses carry carbohydrate-containing proteins on their surface. These glycoproteins are key to the infection process as they are mediators in binding and/or uptake and are thus attractive targets for the development of novel antiviral therapies. Recently, carbohydrate-binding agents were shown to exert *in vitro* antiviral activity towards a number of viruses, including coronaviruses ([@bib155], [@bib11], [@bib9], [@bib10]).

### 3.1.3. Paramyxoviruses

A human monoclonal antibody, palivizumab (Synagis^®^) that targets the RSV fusion protein ([@bib87]) has been approved as a prophylactic therapy for RSV infection, but it is only administered in high-risk pediatric patients. Under preclinical development are the fusion inhibitors VP-14637 ([Fig. 7](#fig7){ref-type="fig"}A) ([@bib50], [@bib51]) and JNJ-2408068 ([Fig. 7](#fig7){ref-type="fig"}B) ([@bib51]), which both interact with the RSV F polyprotein, albeit at different sites, as indicated by the resistance mutations selected in the presence of these inhibitors. Peptides derived from the F protein (the HRN and HRC regions) that interfere with fusion intermediates of F are candidate molecules for impeding virus entry. Fusion peptides derived from human parainfluenza or Hendra virus were shown to inhibit Hendra virus replication *in vitro* ([@bib127]). A similar strategy would also be amenable for coronaviruses ([@bib162]). The ability of peptides that interfere with the class I fusion process has led to the creation of a clinically effective peptide inhibitor of HIV-1 fusion (enfuvirtide, T-20, [Fig. 8](#fig8){ref-type="fig"} ) and related molecules ([@bib53]). The efficacy of T-20 as a therapy for HIV-1 infection supports the concept of designing effective therapies based on understanding the mechanism of viral fusion and the use of peptides as antivirals.Fig. 7Structure of VP-14637 (A) and JNJ-2408068 (B).Fig. 8Structure of enfuvirtide.

Recently, a recombinant fusion protein composed of the catalytic domain of the neuraminidase (sialidase) derived from *Actinomyces viscosus*, fused with a cell-surface-anchoring sequence was reported as a novel broad-spectrum inhibitor of influenza virus replication. The fusion protein is to be applied by aerosol to remove sialic acids (the influenza receptor) from the airway epithelium. A sialidase fusion protein, DAS181 (fludase), has been reported that, at subnanomolar concentrations, inhibits both human and avian influenza virus replication. Significant *in vivo* efficacy of the DAS181 was noted in both prophylactic and therapeutic approaches in experimental influenza virus infections in animals ([@bib102]). The compound is in advanced preclinical development at NexBio.

### 3.1.4. Arenaviruses

A high-throughput screening effort resulted in the identification of a potent and broad-spectrum inhibitor of arenavirus entry ([@bib18]).

3.2. Uncoating
--------------

As discussed for picornaviruses, inhibition of viral uncoating results in inhibition of viral replication. For picornaviruses, the uncoating process is "linked" to receptor binding. For the enveloped viruses, the uncoating process takes place after the virus adsorption and virus--cell fusion processes. Perhaps the best known antiviral uncoating inhibitors are the adamantan(amin)e derivatives, which selectively inhibit the uncoating process of influenza A viruses (see above).

3.3. Translation and processing
-------------------------------

### 3.3.1. Capping and IRES inhibitors

The 5′-capping of viral RNA and Internal Ribosomal Entry Site (IRES)-mediated transcription of viral RNA may also seem to be attractive and largely unexplored targets for antiviral therapy. The following enzymes play a crucial role in the capping machinery: 2′-*O*-methyltransferase, guanylyltransferase and RNA-triphosphatase ([@bib54], [@bib55], [@bib15]). The potential of the methyl transferase as drug target for flaviviruses has recently been demonstrated ([@bib100]). Inhibition of RNA virus replication by targeting the host SAH-hydrolase is discussed in Section [3.3.2](#sec2){ref-type="sec"}. Various inhibitors of the HCV IRES have been synthesized, but none of these have so far proven to be sufficiently potent to warrant further development ([@bib89]).

### 3.3.2. Protease inhibitors {#sec2}

Many RNA viruses encode one or more proteases. Perhaps the best characterized are those of the *Flaviviridae* (HCV and flaviviruses) and of the *Picornaviridae*. Although HCV is not discussed in this review, it is important to mention the successful development of highly potent and selective inhibitors of the HCV NS3 serine protease. Lamarre and his colleages were the first to develop a potent HCV NS3 inhibitor, BILN-2061 ([Fig. 9](#fig9){ref-type="fig"}A) and to demonstrate efficacy of the drug in patients chronically infected with HCV ([@bib94], [@bib124]). Because of cardiotoxicity in experimental models, the development of this compound was discontinued. However, other HCV NS3 protease inhibitors were developed and excellent efficacy has been demonstrated in the clinical setting, the most advanced is VX-950 ([Fig. 9](#fig9){ref-type="fig"}B, [@bib43], [@bib61]). The crystal structure of dengue virus NS3 proteases has been solved ([@bib114]) and the first inhibitors of these enzymes have been reported ([@bib66]).Fig. 9Structure of BILN-2061 (A) and VX-950 (B).

For the prevention and/or treatment of rhinovirus infections, inhibitors of the human rhinovirus (HRV) 3C protease have been extensively investigated. Ruprintrivir ([Fig. 10](#fig10){ref-type="fig"} ) is an irreversible 3C protease inhibitor, which upon intranasal administration in human volunteers, appeared to be safe and well tolerated. In experimentally induced rhinovirus colds in healthy volunteers, prophylaxis with the drug reduced the proportion of subjects with positive viral cultures but did not reduce the frequency of colds ([@bib16], [@bib17]). An analogue of ruprintrivir with excellent oral bioavailability was developed; the compound appeared safe in phase I studies, but has not further progressed toward clinical development ([@bib122], [@bib123]). The crystal structures for the main protease (Mpro) of human coronavirus was determined; this revealed a remarkable degree of conservation with the substrate-binding sites of the picornavirus 3C protease. Molecular modeling suggests that ruprintrivir and analogues may be modified to make them efficient inhibitors of coronavirus (such as SARS-coronavirus) replication ([@bib3], [@bib164], [@bib165]).Fig. 10Structure of ruprintrivir.

3.4. Replication machinery
--------------------------

### 3.4.1. The viral RNA-dependent RNA polymerase

Numerous selective inhibitors of HCV replication have been identified that target the viral RNA-dependent RNA polymerase (RdRp). As in the case for the HIV reverse transcriptase, these compounds can largely been classified as nucleoside and non-nucleoside inhibitors. Nucleoside analogues need to be phosphorylated to their 5′-triphosphate metabolite to inhibit the function of the enzyme at the active site. Non-nucleoside analogues act as allosteric site inhibitors. Several nucleoside and non-nucleoside inhibitors are, or have been, in clinical development for the treatment of infection with HCV ([@bib43]). The nucleoside HCV inhibitors 2′-*C*-methylcytidine ([Fig. 11](#fig11){ref-type="fig"}A), 2′-*C*-methyl-7-deazaguanosine ([Fig. 11](#fig11){ref-type="fig"}B) and related 2′-*C*-methyl nucleosides exert broad-spectrum activity against single plus-stranded RNA viruses, including activity against the picornavirus foot-and-mouth disease virus ([@bib68]). Other nucleoside inhibitors of HCV replication, such as 4′-azidocytidine ([Fig. 11](#fig11){ref-type="fig"}C), a drug that is being developed by Roche, is solely active against HCV ([@bib93] and our unpublished findings). As for HCV, it is also possible to develop highly selective non-nucleoside inhibitors of the polymerase of other RNA viruses, as demonstrated for example with pestiviruses ([@bib7], [@bib120], [@bib121]). Thus, developing potent non-nucleoside inhibitors of related viruses such as other members of the *Flaviviridae* or the highly pathogenic agents covered in this issue, may well be feasible.Fig. 11Structure of 2′-*[C]{.smallcaps}*-methylcydtidine (A), 2′-*C*-methyl-7-deazaguanosine (B) and 4′-azidocytidine (C).

The influenza virus RNA polymerase consists of a complex of three virus-encoded enzymes (PB1, PB2 and PA), which in addition to RNA replicative activity, also contains an endonuclease activity so as to ensure "cap snatching" to initiate the transcription and subsequent translation process ([@bib47]). Only few compounds have been reported that target the influenza polymerase (replicase). Like the inhibitors that have been shown to inhibit the reverse transcriptase (RNA-dependent DNA polymerase) of HIV or the RNA replicase of HCV, influenza replicase inhibitors can (should) in principle also be divided into two classes: nucleosides and non-nucleosides. More than 10 years ago, 2′-deoxy-2′-fluoroguanosine ([Fig. 12](#fig12){ref-type="fig"}A) was described as an inhibitor of influenza virus transcription, although it has not been further studied in this capacity ([@bib152]).Fig. 12Structure of 2′-deoxy-2′-fluoroguanosine (A), T-705 (B) and flutimide (C).

More recently, a substituted pyrazine, T-705 ([Fig. 12](#fig12){ref-type="fig"}B) was reported that has potent *in vitro* activity against influenza A, B and C ([@bib64], [@bib63]). A polymerase inhibitor can be expected to have a resistance profile that does not overlap with those of the neuraminidase or M2 inhibitors. According to a comparative study, T-705 would even be more potent than oseltamivir when increasing the multiplicity of infection (*in vitro*) or using a higher virus challenge dose (*in vivo*) ([@bib149]). Against avian influenza A (H5N1), T-705 was found to be less effective than oseltamivir in cell culture, but more effective than ribavirin ([@bib142]). T-705 proved also to be effective, when administered orally, against a lethal avian influenza A virus infection in mice ([@bib142]). It has been postulated that T-705 is converted intracellularly to the ribonucleotide T-705-ribofuranosyl-5′-monophosphate (T-705 RMP) by a phosphoribosyl transferase, and, upon phosphorylation to its 5′-triphosphate, T-705 RTP would inhibit influenza virus RNA polymerase in a GTP-competitive manner ([@bib63], [Fig. 13](#fig13){ref-type="fig"} ). Unlike ribavirin 5′-monophosphate, T-705 RMP does not significantly inhibit IMP dehydrogenase, indicating that it may owe its anti-influenza virus activity mainly, if not exclusively, to inhibition of the influenza virus RNA polymerase.Fig. 13Intracellular metabolism and mechanism of action of T-705 against influenza A virus. T-705 would first be converted to its ribonucleotide (T-705 RMP), which would subsequently be converted to its 5′-triphosphate (T-705 RTP) that would then inhibit influenza virus RNA polymerase through competition with GTP ([@bib63]).

The "cap snatching" or "cap scavenging" endonuclease activity associated with the influenza polymerase complex may be an attractive target for drug therapy. A number of molecules have been shown to inhibit the influenza endonuclease activity. Flutimide ([Fig. 12](#fig12){ref-type="fig"}C), a 2,6-diketopiperazine isolated from extracts of the fungal species *Delitschia confertaspora*, inhibits the cap-dependent endonuclease activity and influenza virus (A and B strains) replication in cell culture ([@bib153]).

Recently, the anti-influenza inhibitor T-705 has also been accredited with both *in vitro* and *in vivo* activities against a panel of arenaviruses (Pichinde) and bunyaviruses (Punta Toro) ([@bib73]). In general, T-705 was more active than ribavirin, as reflected by substantially greater therapeutic indexes and it was suggested that T-705 may be a viable alternative for the treatment of life-threatening infections with bunya- or arenaviruses ([@bib73]). It may be assumed that the mechanism by which T-705 inhibits the replication of bunya- and arenaviruses, is similar to the mechanism by which it presumably inhibits influenza replication, that is inhibition of the viral polymerases by T-705-ribofuranosyl-5′-triphosphate.

### 3.4.2. The viral helicase and the herewith associated NTPase

Almost all RNA viruses encode a helicase/NTPase that is responsible for the unwinding of the double-stranded RNA formed during replication. The helicase may represent an attractive target for therapy. There have been substantial efforts to identify inhibitors of the HCV NS3 helicase/NTPase. Inhibitors of both functions have been described, but have so far not been further developed ([@bib62], [@bib19], [@bib154]). We recently identified a class of thiazolobenzimidazoles ([Fig. 14](#fig14){ref-type="fig"} ) as potent inhibitors of the replication of various enteroviruses ([@bib46]). Mechanistic studies indicate that the compounds target the picornavirus 2C gene product, which has been predicted to be a helicase/NTPase. Coxsackie virus 2C was expressed and shown to have functional NTPase activity, that, however, was not inhibited by this class of compounds ([@bib45]). Nevertheless, our unpublished data suggest that the thiazolibenzimidazoles might interfere with the assembly/functioning of the viral helicase. The helicase can be considered as a valuable but yet largely unexplored target for antiviral therapy.Fig. 14General structure of thiazolobenzimidazoles.

3.5. Assembly
-------------

Recently a novel inhibitor of RSV replication has been identified, the benzodiazepine RSV604 ([Fig. 15](#fig15){ref-type="fig"} ), the first of a new class of RSV inhibitors (currently in phase II clinical trials) that appear to be targeted at the viral nucleocapsid (N) protein ([@bib30]). This compound may possibly prevent the assembly of the virus particles. RSV604 represents one of the most promising candidate drugs to date for the treatment of RSV infections in humans.Fig. 15Structure of RSV604.

3.6. Release
------------

An essential step in the viral life cycle is the release of the new progeny virions from the infected cell. As discussed in Section [2.1](#sec1){ref-type="sec"} this process has been extensively studied for influenza virus, resulting in the identification of the neuraminidase inhibitors. For many other RNA viruses, there is very little information about the precise molecular events leading to release of the progeny virions.

4. Cellular targets for therapy
===============================

Quite a number of antiviral agents have been reported to be targeted at cellular factors. Some of them may prevent the interaction of a cellular factor with the replication machinery of the virus, while others may influence host cell metabolism in such a way that efficient viral replication is prevented.

4.1. Essential virus/host interactions
--------------------------------------

Various host cell factors play a key role in the efficient replication of RNA viruses. In 2004, it was discovered that the immunosuppressive agent cyclosporin A inhibits HCV replication *in vitro* ([@bib116]). It was proposed that this effect is mediated by blockade of cyclophilins ([@bib117]) and that cyclosporin A ([Fig. 16](#fig16){ref-type="fig"}A) would suppress HCV replication at the level of the HCV RNA polymerase ([@bib158]). More specifically, cyclosporin A would block the ability of peptidyl-prolyl *cis*--*trans* isomerase (PPIase), cyclophilin B (CyPB), to bind to the RNA replicase (NS5B), thus inhibiting the function of the RNA replicase ([@bib131]).Fig. 16Structure of cyclosporine A (A) and Debio-025 (B).

We reported that Debio-025 ([Fig. 16](#fig16){ref-type="fig"}B), a non-immunosuppressive analogue of CsA, is a much more potent inhibitor of HCV replication than CsA ([@bib119]). Our recent data indicate that the mechanism of action of Debio-025 and cyclosporin A may be different from the proposed interaction with NS5B ([@bib34]). Debio-025 is currently in phase II clinical studies for the treatment of HCV infections. The clinical efficacy of Debio-025 in the treatment of HCV infections supports the concept that molecules that prevent crucial interactions between viral and cellular factors may be interesting antiviral agents. The advantage of such approach (as we have also shown for Debio-025) is that it may make antiviral resistance development more difficult.

4.2. Glycosylation inhibitors
-----------------------------

Endoplasmic reticulum (ER) alpha-glucosidase inhibitors, which block the trimming step of N-linked glycosylation, have been shown to impede the production of several ER-budding viruses, including flavi- and pestiviruses as well as HCV ([@bib49], [@bib160]). In a lethal mouse model of Japanese encephalitis, oral delivery of *N*-nonyl-deoxynojirimycin ([Fig. 17](#fig17){ref-type="fig"} ) reduced the mortality rate ([@bib160]).Fig. 17Structure of *N*-nonyl-deoxynojirimycin.

4.3. Compounds that interfere with nucleoside metabolism
--------------------------------------------------------

Since viral replication predominantly relies on building blocks present in the host cell, it is apparent that interfering with this supply will slow down or halt the production of progeny viruses. However, antiviral drugs that target the nucleoside metabolism of the host cell will not only result in inhibition of viral replication, but will also be endowed with a cytotoxic and/or cytostatic effect. Thus, although these compounds may prove to be antivirally active, they lack selectivity.

### 4.3.1. IMP dehydrogenase inhibitors

As discussed earlier, inhibition of IMP dehydrogenase results in a depletion of the intracellular GTP-pools, which contributes to the antiviral activity of ribavirin and structurally related molecules such as viramidine, EICAR and structurally unrelated compounds such as mycophenolic acid ([Fig. 18](#fig18){ref-type="fig"} ) and VX-497, which are putatively targeted at the coenzyme (NAD^+^) rather than the apoenzyme (at which the ribavirin congeners are targeted).Fig. 18Structure of mycophenolic acid.

### 4.3.2. SAH hydrolase inhibitors

Ever since *S*-adenosylhomocysteine hydrolase (SAH) was recognized as a pharmacological target for antiviral agents ([@bib111]), an increasing number of adenosine, acyclic adenosine and carbocyclic adenosine analogues have been described as potent SAH hydrolase inhibitors endowed with broad-spectrum antiviral activity ([@bib41]). The antiviral activity spectrum of SAH hydrolase inhibitors against RNA viruses includes rhabdo-, filo-, arena-, paramyxo-, reo-, and retroviruses. Among the most potent SAH hydrolase inhibitors and antiviral agents rank carbocyclic 3-deazaadenosine (C-c^3^Ado, [Fig. 19](#fig19){ref-type="fig"}A), neplanocin A ([Fig. 19](#fig19){ref-type="fig"}B), 3-deazaneplanocin A ([Fig. 19](#fig19){ref-type="fig"}C), the 5′-nor derivatives of carbocyclic adenosine (C-Ado, aristeromycin, [Fig. 19](#fig19){ref-type="fig"}D), and the 2-halo (2-fluoro) and 6′-*R*-alkyl (6′-methyl) derivatives of neplanocin A.Fig. 19Structure of carbocyclic 3-deaza-adenosine (A), neplanocin A (B), 3-deazaneplanocin A (C) and aristeromycin (D).

These compounds are particularly active against rhabdoviruses, and have proven to be effective against filoviruses such as Ebola virus ([@bib84]). In fact, when administered as a single dose of 1 mg/kg on the first or second day after an Ebola Zaire virus infection in mice, 3-deazaneplanocin A reduced peak viremia by more than 1000-fold compared with mock-treated controls, and most or all of the animals survived ([@bib24]). This protective effect was accompanied, and probably mediated, by the production of high concentration of IFN-α in the Ebola virus-infected mice ([@bib25]). It could be postulated that by blocking the 5′-capping of the nascent viral (+)RNA strands, of which the maturation is dependent on methylation ([Fig. 20](#fig20){ref-type="fig"} ), 3-deazaneplanocin A prevented the dissociation of these strands from the viral (−)RNA genome, thereby leading to an accumulation of replicative intermediates. These replicative intermediates (containing double-stranded RNA stretches) could, according to the concept proposed many years ago ([@bib28]), be implicated in the high-level production of interferon.Fig. 20Mechanism of action of *S*-adenosylhomocysteine hydrolase (SAH) inhibitors. SAH is a product-inhibitor of methylation reactions including those that are required for the maturation (5′-capping) of viral mRNAs. Through the hydrolysis of SAH, SAH hydrolase prevents the accumulation of SAH that would otherwise lead to inhibition of the SAM-dependent methylation reaction.

### 4.3.3. OMP decarboxylase inhibitors

Pyrazofurin \[3-(β-[d]{.smallcaps}-ribofuranosyl)-4-hydroxypyrazole-5-carboxamide, [Fig. 21](#fig21){ref-type="fig"}A\], as prototype of the OMP decarboxylase inhibitors, is active against both (+)RNA viruses \[picornaviruses (poliovirus, Coxsackie B4), togaviruses (Sindbis)\] and (−)RNA viruses \[paramyxoviruses (measles, RSV), orthomyxoviruses (influenza A, B, C), rhabdoviruses (vesicular stomatitis virus) and arenaviruses (Junin, Tacaribe)\] ([@bib4], [@bib5], [@bib139]). Also paramyxoviruses, RSV ([@bib90]) and measles virus ([@bib80]) have been reported to be sensitive to inhibition by pyrazofurin. Recently, this also has been proven to be the case for Nipah virus, another paramyxovirus ([@bib67]).Fig. 21Structure of pyrazofurin (A) and 6-azauridine (B).

To act as an OMP decarboxylase inhibitor, pyrazofurin must first be converted by cellular kinase(s) to its 5′-monophosphate ([Fig. 22](#fig22){ref-type="fig"} ). Another compound known to interfere with the conversion of OMP to UMP is 6-azauridine ([Fig. 21](#fig21){ref-type="fig"}B), and this again requires intracellular phosphorylation of the compound to its 5′-monophosphate. Not much is known about the antiviral activity spectrum of 6-azauridine ([@bib129]). However, this should be similar to that of pyrazofurin. Like pyrazofurin, 6-azauridine has been found to be effective against Nipah virus ([@bib67]).Fig. 22Mechanisms of action of OMP decarboxylase inhibitors and CTP synthetase inhibitors. OMP decarboxylase inhibitors (pyrazofurin, 6-azauridine) need to be phosphorylated to their 5′-monophosphate before they are able to interact with OMP decarboxylase. CTP synthetase inhibitors (C-Cyd, Ce-Cyd) need to be phosphorylated to their 5′-triphosphate before they are able to interact with CTP synthetase.

### 4.3.4. CTP synthetase inhibitors

The carbocyclic analogues of the normal nucleoside cytidine, such as cyclopentylcytosine (C-Cyd, carbodine) ([Fig. 23](#fig23){ref-type="fig"}A) and cyclopentenylcytosine (Ce-Cyd) ([Fig. 23](#fig23){ref-type="fig"}B) have been considered as potential antiviral and antitumor agents. C-Cyd was first described as an anti-influenza virus agent ([@bib138]), but it has also shown activity against DNA viruses \[poxviruses (vaccinia)\], (+)RNA viruses \[togaviruses (Sindbis, Semliki forest)\], (−)RNA viruses \[orthomyxoviruses (influenza), paramyxoviruses (parainfluenza, measles), rhabdoviruses (vesicular stomatitis)\] and dsRNA viruses (reovirus) ([@bib39]). Ce-Cyd is a more potent antiviral agent than its counterpart, C-Cyd, and, in addition, it has also proved active against picornaviruses (poliovirus, Coxsackie B, rhinovirus) and herpesviruses ([@bib40]). The antiviral activity spectrum of Ce-Cyd extends to bunyaviruses (Punta Toro), flaviviruses (Japanese encephalitis) and arenaviruses (Junin, Tacaribe) ([@bib106], [@bib4]). For both the antitumor and antiviral effects of C-Cyd and Ce-Cyd, the putative target is assumed to be CTP synthetase, the enzyme that catalyses the conversion of UTP to CTP, which is the final step in the *de novo* pyrimidine biosynthetic pathway. The fact that both the antiviral and cytotoxic effect of C-Cyd and Ce-Cyd are readily reversed by cytidine and, to a lesser extent, by uridine, but not at all by other nucleosides, such as 2′-deoxythymidine or 2′-deoxycytidine, supports this hypothesis.Fig. 23Structure of cyclopentylcytosine (A) and cyclopentylcytosine (B).

5. Conclusion
=============

Many targets exist for selective inhibition of the replication of RNA viruses, some of which have been discussed in this paper. Many other (potential) interesting targets have remained unexplored. Concerted efforts of dedicated laboratories acting in international networks, such as the VIZIER network, described by Coutard et al. (this issue), that study the structural genomics of enzymes involved in RNA virus replication may be instrumental in identifying novel antiviral strategies to inhibit RNA virus resplication. For example, it may be assumed that the strictly regulated nuclear import of the eight influenza RNA segments or the encapsidation of one single copy of each of these RNA segment into the progeny viral particles, may represent potential targets for therapeutic intervention ([@bib75]). Although it is technically feasible to develop drugs for the treatment of various families or genera of RNA viruses (for example flaviviruses, orthomyxoviruses, paramyxoviruses, picornaviruses, etc.), the pharmaceutical industry is unlikely to develop antivirals for diseases for which the market is too small or uncertain. Ideally, antiviral drugs should be developed that exert broad-spectrum anti-RNA virus activity. The fact that the influenza polymerase inhibitor T-705 also inhibits the replication of other RNA viruses ([@bib73]) and that 2′-*C*-methyl nucleoside analogue inhibitors of the HCV RdRp inhibit also the replication of various other (+)ssRNA viruses, suggest that nucleoside polymerase inhibitors may likely to be broad-spectrum antiviral drug candidates. If such drugs were to be licensed for the treatment of such frequent infections as influenza or HCV, they could eventually be used "off-label", or on a compassionate basis, for the treatment of other important, but less common infections with highly pathogenic RNA viruses.
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